SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (749)11/20/2006 5:22:35 PM
From: VanBio  Read Replies (1) of 933
 
Millenium makes sense to me as a partner or as an aquirer, but there could be a number of potential suitors including Roche, Celgene, MGI, or maybe Cephalon. Celgene could use it's high stock price to make an acquisition before significant competition hits the thalidomide franchise. There are a bunch of HSP90 presentations and posters at American Society of Hematology in Dec. so maybe there will be more interest after some data is presented. Companies may be trying to decide which pony to ride. Good luck.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News